Research
| Current Projects The
Division of
Vascular/Interventional Radiology is
dedicated full time to the mission of
patient care and research for the
development of interventional procedures. Phase 3
Prospective, Randomized,
Blinded, and Controlled Investigation of
HepaSphere/QuadraSphere Microspheres
for Delivery of Doxorubicin for the
Treatment of Hepatocellular Carcinoma The purpose of this study is to
evaluate overall survival in patients
treated with HepaSphere/QuadraSphere compared
to conventional transarterial
chemoembolization with particle PVA. The Gore
FREEDOM Study: GORE Flow
Reversal System and GORE Embolic Filter
Extension Study for the Ongoing
Collection of Patient Outcomes The objective of this study is to
provide an ongoing evaluation of clinical
outcomes associated with the GORE Flow
Reversal System and the GORE Embolic
Filter when used for embolic protection during
carotid artery stenting. Acute
Venous Thrombosis: Thrombus
Removal With Adjunctive Catheter-Directed
Thrombolysis--The ATTRACT Trial The purpose of this study is to
determine if the use of adjunctive
Pharmacomechanical Catheter Directed
Thrombolysis, which includes the
intrathrombus administration of
rt-PA--Activase (Alteplase),can prevent the
post-thrombotic syndrome(PTS)in patients with
symptomatic proximal deep vein
thrombosis (DVT) as compared with optimal
standard DVT therapy alone. The GORE®
VIATORR® TIPS Endoprosthesis Versus
Large-Volume Paracentesis for the Treatment
of Ascites in Patients With Portal
Hypertension The purpose of
this study is to demonstrate that TIPS with
the GORE® VIATORR® TIPS
Endoprosthesis improves transplant-free
survival compared to LVP in patients
with cirrhosis and difficult to treat ascites. TheraSphere
Yttrium-90 Glass:
Humanitarian Device Exemption Use Protocol
for TheraSpherefor
Treatment of Unresectable Hepatocellular
Carcinoma The purpose of this protocol is to
provide TheraSphere
treatment for patients with liver cancer who
cannot be treated by surgery. The
effect on the tumor and any side effects of
TheraSphere treatment will be
examined. This study will provide supervised
and limited access to TheraSphere
treatment at the Medical University of South
Carolina. TheraSphere is a medical device
containing yttrium-90 (Y-90), a radioactive
material that has been used previously in the
treatment of liver tumors. When
Y-90 is incorporated into very tiny glass
beads (TheraSphere), it can be
injected to the liver through blood vessels
supplying the liver. This allows a
large dose of radiation to be delivered to the
tumor with less risk of toxic
effects from radiation to other parts of the
body or to healthy liver tissue.
The radiation from TheraSphere is contained
within the body and becomes
minimally active within 7 days after treatment
due to physical decay. The glass
beads remain in the body, but do not cause any
health problems. TheraSphere has
been approved for use in the treatment of
liver cancer in the United States by
the Food and Drug Administration on a limited
basis. Revised
7/20/2012
|